These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3828960)

  • 1. Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy.
    Benson RC; Gorman PA; O'Brien PC; Holicky EL; Veneziale CM
    Cancer; 1987 May; 59(9):1599-606. PubMed ID: 3828960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
    Noordzij MA; Bogdanowicz JF; van Krimpen C; van der Kwast TH; van Steenbrugge GJ
    J Urol; 1997 Nov; 158(5):1880-4; discussion 1884-5. PubMed ID: 9334622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of nuclear androgen receptor quantification to human prostatic adenocarcinoma.
    Fentie DD; Lakey WH; McBlain WA
    J Urol; 1986 Jan; 135(1):167-73. PubMed ID: 3941459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy.
    van Aubel OG; Bolt-de Vries J; Blankenstein MA; de Jong FH; Schröder FH
    Urol Res; 1989; 17(2):99-102. PubMed ID: 2734984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients.
    Gorelic LS; Lamm DL; Ramzy I; Radwin HM; Shain SA
    Cancer; 1987 Jul; 60(2):211-9. PubMed ID: 3594358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate.
    Nabi G; Seth A; Dinda AK; Gupta NP
    J Clin Pathol; 2004 Feb; 57(2):146-50. PubMed ID: 14747438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptors in cancer of the prostate. Correlation with the stage and grade of the tumor.
    Habib FK; Odoma S; Busuttil A; Chisholm GD
    Cancer; 1986 Jun; 57(12):2351-6. PubMed ID: 2421868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer.
    van Aubel O; Bolt-de Vries J; Blankenstein MA; Schröder FH
    Prostate; 1988; 12(3):191-8. PubMed ID: 3375141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor binding activity in human prostate cancer.
    Benson RC; Utz DC; Holicky E; Veneziale CM
    Cancer; 1985 Jan; 55(2):382-8. PubMed ID: 2578085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy.
    Prins GS; Sklarew RJ; Pertschuk LP
    J Urol; 1998 Mar; 159(3):641-9. PubMed ID: 9474117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer.
    Trachtenberg J; Walsh PC
    J Urol; 1982 Mar; 127(3):466-71. PubMed ID: 7062420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the androgen receptor pathway during progression of prostate cancer.
    Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
    Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
    Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
    Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma.
    Takeda H; Akakura K; Masai M; Akimoto S; Yatani R; Shimazaki J
    Cancer; 1996 Mar; 77(5):934-40. PubMed ID: 8608487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of androgen receptor content in advanced prostate cancer.
    Magi-Galluzzi C; Xu X; Hlatky L; Hahnfeldt P; Kaplan I; Hsiao P; Chang C; Loda M
    Mod Pathol; 1997 Aug; 10(8):839-45. PubMed ID: 9267828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.
    Hong H; Kao C; Jeng MH; Eble JN; Koch MO; Gardner TA; Zhang S; Li L; Pan CX; Hu Z; MacLennan GT; Cheng L
    Cancer; 2004 Jul; 101(1):83-9. PubMed ID: 15221992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy.
    Sadi MV; Walsh PC; Barrack ER
    Cancer; 1991 Jun; 67(12):3057-64. PubMed ID: 1710537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hormone-sensitive metastatic prostate cancer.
    Agarwal N; Hussain M
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1221-41, viii. PubMed ID: 24188260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.